Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)

Journal of Mental Health

Volumn 19, Issue 2, 2010, Pages 168-175

  Thomas, Shibu P ^a   Nandhra, Harpal Singh ^b   Jayaraman, Anand ^c  

^a St Michaels Hospital   (United Kingdom)

^b Ashton House   (United Kingdom)

^c Maindiff Court Hospital   (United Kingdom)

Author keywords

Depression; Lamotrigine; Therapeutics

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE;

ADD ON THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HUMAN; MAJOR DEPRESSION; PRACTICE GUIDELINE; QUALITY CONTROL; TREATMENT OUTCOME; TREATMENT RESISTANT UNIPOLAR DEPRESSION;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; QUESTIONNAIRES; TRIAZINES; YOUNG ADULT;

EID: 77950810570     PISSN: 09638237     EISSN: 13600567     Source Type: Journal    
DOI: 10.3109/09638230903469269     Document Type: Article

References (23)

1. Barbosa, L., Berk, M., & Vorster, M. (2003). A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry, 64, 403-407.
2. Baloescu, A., Grigorescu, G., & Gheorghe, M.D. (2006). Lamotrigine in the treatment of resistant depression. 14th Association of European Psychiatrists Congress, 2006, Abst 093.
3. Barbee, J.G., & Jambour, N.J. (2002). Lamotrigine as an augmentation agent in treatment-resistant depression. Journal of Clinical Psychiatry, 63(8), 737-741.
4. Bauer, M., Forsthoff, A., Baethge, C., Adli, M., Berghofer, A., Dopfmer, S., & Bschor, T. (2003). Lithium augmentation therapy in refractory depression - Update. European Archives of Psychiatry & Clinical Neuroscience, 253, 132-139. (Pubitemid 37205472)
5. Bourin, M.,Masse, F., & Hascoet, M. (2005). Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. Journal of Psychiatry & Neuroscience, 30(4), 275-282.
6. Cowen, P.J. (2005). New drugs, old problems. Revisiting. . . pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment, 11, 19-27.
7. Dimellis, D., & Kouniakis, F. (2004). Lamotrigine as an adjunctive agent for treatment resistant depressed patients already treated with sertraline - An open-label study. International Journal of Neuropsychopharmacology, 2, S162.
8. Fava, M., Rush, A.J., Trivedi, M.H., Nierenberg, A.A., Thase, M.E., Sackeim, H.A., Quitkin, F.M., Wisniewshi, S., Lavori, P.W., Rosenbaum, J.F., & Kupfer, D.J. (2003). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D). Psychiatric Clinics of North America, 26, 457-494.
9. Gabriel, A. (2006). Lamotrigine adjunctive treatment in resistant unipolar depression: An open, descriptive study. Depression & Anxiety, 23(8), 485-488.
10. Geddes, J.R., Calabrese, J.R., & Goodwin, G.M. (2009). Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry, 194(1), 4-9.
11. Gutierrez, R.L., McKercher, R.M., Galea, J., & Jamison, K.L. (2005). Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectrum, 10(10), 800-805.
12. Kendler, K.S., Neale, M.C., Kessler, R.C., Heath, A.C., & Eaves, L.J. (1992). A population-based twin study of major depression in women. The impact of varying definitions of illness. Archives of General Psychiatry, 49, 257-266.
13. Kessler, R.C., McGonagle, K.A., Zhao, C., Nelson, C.B., Hughes, M., Eshleman, S., Wittchen, H.U., & Kendler, K.S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8-19.
14. Kouniakis, D. (2004). Lamotrigine as an adjunctive agent for treatment resistant depressed patients already treated with sertraline - An open-label study. International Journal of Neuropsychopharmacology, 7(2), s162.
15. Nierenberg, A.A., & Amsterdam, J.D. (1990). Treatment-resistant depression: Definition and treatment approaches. Journal of Clinical Psychiatry, 51(Suppl. 6), 39-47.
16. Rocha, F.L., & Hara, C. (2003). Lamotrigine augmentation in unipolar depression. International Clinical Psychopharmacology, 18(2), 97-99.
17. Rybakowski, J., & Tuszewska, M. (2006). Lithium or lamotrigine augmentation in treatment-resistant depression. International Journal of Neuropsychopharmacology, 9(Suppl. 1), s232, 03-025.
18. Schindler, F., & Anghelescu, I. (2004). The LILA-Study: An observational study comparing the efficacy of lithium vs. lamotrigine as an augmentation strategy for treatmemt- resistant depression (TRD). 59th Annual Meeting of the Society of Biological Psychiatry (SOBP), New York, 2004, Abst 140.
19. Schindler, F., & Anghelescu, I. (2007). Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: A randomised, open-label study. International Clinical Psychopharmacology, 22(3), 179-182
20. Shergill, S.S., & Katona, C.L. (1997). Pharmacological choices after one antidepressant fail: A survey of UK psychiatrists. Journal of Affective Disorders, 43(1), 19-25.
21. Trivedi, M.H., Rush, A.J., Crismon, M.L., Kashner, T.M., Toprac, M.G., Carmody, T.J., Key, T., Biggs, M.M., Shores-Wilson, K., Witte, B., Suppes, T., Miller, A.L., Altshuler, K.Z., & Shon, S.P. (2004). Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Archives of General Psychiatry, 61, 669-680.
22. Valenstein, M., McCarthy, J.F., Austin, K.L., Greden, J.F., Young, E.A., Blow, F.C. (2006). What happened to lithium? Antidepressant augmentation in clinical settings. American Journal of Psychiatry, 163, 1219-1225.
23. Vinod, K.Y., & Subhash, M.N. (2002). Lamotrigine induced selective changes in 5-HT (1A) receptor mediated response in rat brain. Neurochemical International, 40, 315-319.